NCT00915837View on ClinicalTrials.gov

Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2009

Conditions
Diabetic Macular Edema
Interventions
DRUG

triamcinolone acetonide

Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day

DRUG

triamcinolone acetonide

Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day

Trial Locations (4)

48201

Kresege Eye Institute, Detroit

55435

VitreoRetinal Surgery, PA, Edina

85014

Retinal Consultants of Arizona, Phoenix

93103

California Retina Consultants, Santa Barbara

All Listed Sponsors
lead

SurModics, Inc.

INDUSTRY

NCT00915837 - Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema | Biotech Hunter | Biotech Hunter